Healthcare / BiotechnologyNasdaqGM
$1.71
-0.13 (-7.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-52.7M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$198M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-46.3M · FCF $-20.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $632000.00 | $-1.6M |
| Net Income | $-46.3M | $-46.3M | $-22.2M | $-207.7M | $-371.1M |
| EBITDA | $-93.4M | $-93.4M | $-50.4M | $-47.9M | $-51.7M |
| EPS | — | — | -0.28 | -2.33 | -4.24 |
| Gross Margin | — | — | — | 617.1% | 2325.1% |
| Operating Margin | — | — | — | -7749.4% | 3422.2% |
| Net Margin | — | — | — | -32868.5% | 23923.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 |
| Current Ratio | 8.09 | 8.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-20.6M | $-20.6M | $-52.7M | $-72.9M | $-51.7M |
| Returns | |||||
| ROE | -20.0% | -20.0% | -11.1% | -85.6% | -88.0% |
| Valuation | |||||
| P/B | 1.96 | 1.96 | 0.38 | 0.78 | 1.09 |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | 140.7% | — |
| EPS Growth | — | — | 88.2% | 44.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+30.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.28 → n/d
Residual
+30.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.